Following last month’s dismissal of the securities class action complaint against Illumina Inc. and its former spinoff company, GRAIL, the plaintiffs have refiled an amended complaint, keeping the action alive.
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
Recent results from the PATHFINDER 2 study showed that the addition of GRAIL’s multi-cancer detection test to standard screening led to a seven-fold increase in cancers detected within a year, the company said.
Testing of chemicals for potential cancer causation (carcinogenesis) has long been a successful disease-prevention initiative of the highest priority.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
We are rapidly approaching the Sept. 30 planned expiration of telemedicine coverage under Medicaid. Letting this authorization expire is short-sighted. As an oncologist, I believe there are multiple compelling, non-pandemic reasons for telemedicine to remain a permanent fixture in cancer care.
The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.
Nearly half of cancer patients and survivors in the United States face medical debt so crushing that it has sparked a relatively new focus within oncology: financial toxicity.
Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.1,2
Don’t try to convince Col. Susan Fondy that lymphedema doesn’t merit interest from medical researchers.
